PRA Named a Scrip Awards Finalist

RALEIGH, N.C., Sept. 16, 2011 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces our selection as a finalist in the Best CRO category of the 2011 Scrip Awards. The winner will be announced at the Scrip Awards presentation being held at the Grosvenor House Hotel in London on 3 November 2011.

Selections for the shortlist were based on the CRO's performance from June 2010 through July 2011. Judges evaluated each CRO's ability to focus on innovations in patient recruitment strategy; demonstrate a wide range of capabilities and strengths; deliver results and exceed client expectations; improve performance; and streamline data collection and reporting.

"This recognition is a testament to the innovative and effective work that PRA has been doing for our customers," said Tami Klerr-Naivar, PRA's Senior Vice President of Business Development. "We are proud to be considered for this significant award, which provides the opportunity to demonstrate our continued growth and excellence in the clinical research market."

With over 4100 employees, PRA offers a wide range of services across Phases I-IV.  In addition to a full suite of product registration services, our Early Development Services unit conducts Phase I – IIa studies through our United States and European clinics and our Late Phase Services group specializes in Phase IIIb – IV and registry studies.  

About PRA

PRA is transforming clinical trials through our people, innovation and transparency.  PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge.  Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.  But at PRA, we are looking to the future, not the past.  Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email [email protected] or call our Global Headquarters.

SOURCE PRA